Intrathecal rhGNS Enzyme for MPS IIID Brain Delivery
Solution Overview
Problem
There is no effective treatment available for mucopolysaccharidosis type IIID (MPS IIID), a neurodegenerative lysosomal storage disorder characterized by progressive cognitive decline and motor skill deterioration, due to the lack of therapies targeting the brain effectively.
Innovation Solution
A method involving the use of a recombinant human acetylglucosamine-6-sulfatase (rhGNS) protein, specifically designed to be administered intrathecally, which mimics the natural enzyme to break down heparan sulfate, thereby reducing glycosaminoglycan storage in cells and alleviating neurologic symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional enzyme replacement therapy is used for MPS IIID, then the treatment can address systemic symptoms, but it cannot effectively treat neurologic symptoms because the enzyme cannot cross the blood-brain barrier
Solution Approach 1:
The patent uses intrathecally administered recombinant human acetylglucosamine-6-sulfatase as an intermediary substance that directly enters the central nervous system through the cerebrospinal fluid, bypassing the blood-brain barrier obstacle. This mediator approach allows the enzyme to reach its target site (lysosomes in neural cells) without requiring complex delivery systems like viral vectors or nanocarriers.
Solution Approach 2:
The patent changes the delivery dimension from systemic circulation (bloodstream) to direct central nervous system access (cerebrospinal fluid space). By administering the enzyme intrathecally into the subarachnoid space, the treatment exploits the third dimension of CSF flow to distribute the enzyme throughout the CNS, achieving brain penetration without complex trans-barrier mechanisms.
2Reliability
If MPS IIID is left untreated, then the disease progresses to severe neurologic decline and death, but available treatments do not address the underlying enzymatic deficiency in the brain
Solution Approach 1:
The recombinant human acetylglucosamine-6-sulfatase enzyme performs its natural physiological function of breaking down heparan sulfate substrates within lysosomes. The enzyme is self-sufficient in its catalytic activity and does not require complex delivery vehicles, genetic modification of patient cells, or immunosuppressive regimens. It simply replaces the missing enzyme and restores normal metabolic function in neural tissues.
Solution Approach 2:
The patent changes the physical-chemical parameters of enzyme delivery by using intrathecal administration to achieve high local concentrations of the enzyme in the cerebrospinal fluid and brain parenchyma. This parameter change (delivery route and concentration) enables effective therapy where conventional systemic administration fails, making the treatment practically available for neurologic disease modification.
3Stability of the object's composition
If the testing buffer contains high concentrations of sodium, citrate, phosphate, or sulfate, then the buffer capacity is adequate, but the sulfatase activity of the recombinant polypeptide is inhibited
Solution Approach 1:
The patent optimizes the chemical parameters of the testing buffer by limiting sodium to less than 500 mM, citrate to less than 100 mM, phosphate to less than 100 mM, and sulfate to less than 100 mM, while maintaining adequate buffer capacity through pH control (5.0-6.0) and ionic strength adjustment. These parameter changes eliminate substrate inhibition of the sulfatase enzyme while preserving buffer stability for reliable activity measurement.
Solution Approach 2:
The patent replaces conventional high-ionic-strength buffering systems with a low-ionic-strength buffer formulation that relies on organic detergent (Triton X-100) for solubilization and stability rather than high concentrations of inorganic ions. This substitution eliminates the trade-off between buffer capacity and enzymatic activity by using a different stabilization mechanism that is compatible with sulfatase function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The rhGNS protein effectively enters human MPS IIID cells, targets lysosomes, and significantly reduces glycosaminoglycan storage, demonstrating potential in treating the underlying causes of neurologic decline associated with MPS IIID.
Implementation Method 1
the recombinant polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence (a) having at least 95% sequence identity to SEQ ID NO: 1 and (b) having the enzymatic activity of human acetylglucosamine-6-sulfatase (GNS)
Implementation Method 2
testing the sulfatase activity of a recombinant polypeptide in a testing buffer comprising less than 500 mM sodium, less than 100 mM citrate, less than 100 mM phosphate, less than 100 mM sulfate, and at least 0.005% Triton X-100
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present disclosure relates to compositions for use in a method of treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mucopolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a recombinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the enzymatic activity of the human GNS protein. The composition can be tested in a testing buffer comprising less than 500 mM sodium, less than 100 mM citrate, less than 100 mM phosphate, less than 100 mM sulfate, and at least 0.005% Triton X-100 at a pH of about 5.6.